Hypertriglyceridemia: Practice Essentials, Pathophysiology, Etiology. Wu CW, Lin PY, Liu YF, Liu TC, Lin MW, Chen WM, et al. Central corneal mosaic opacities in Schnyder's crystalline dystrophy. FREDRICKSON DS, LEES RS. A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal metabolism. ![]() Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. Christoph Wanner, M.D., Vera Krane, M.D., Winfried März, M.D.![]() ![]() Scriver CR, Beaudet AR, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: Mc. Graw- Hill; 2. Structure and function of the plasma lipoproteins and their receptors. Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. ![]() Philadelphia, Pa: Lippincott- Raven; 8. Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. ![]() Epidemiology Background. ASCVD, including CAD, stroke, and PAD, have been a great burden in public health among Taiwanese citizens, and hyperlipidemia plays an. These highlights do not include all the information needed to use LIPITOR safely and effectively. See full prescribing information for LIPITOR. Prev Next The heart is a muscular organ about the size of a fist, located just behind and slightly left of the. What to Eat When You Have Stage 1 or 2 Kidney Disease. Disclaimer: This article is for informational purposes only and is not intended to be a substitute for medical. At the time of HIV diagnosis, all patients should be screened for renal dysfunction with a urinalysis (UA) and a calculated estimate of renal function. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Huang Y, Schwendner SW, Rall SC Jr, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. ![]() ![]() Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Feussner G, Piesch S, Dobmeyer J, Fischer C. Genetics of type III hyperlipoproteinemia. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga- Thie GM. Pathophysiology of hypertriglyceridemia. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Pajukanta P, Porkka KV. Genetics of familial combined hyperlipidemia. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP. Primary and secondary hypertriglyceridaemia. Pilia G, Chen WM, Scuteri A, Orr. Heritability of cardiovascular and personality traits in 6,1. Sardinians. Finding genes and variants for lipid levels after genome- wide association analysis. Excess of rare variants in genes identified by genome- wide association study of hypertriglyceridemia. Common variants at 3. Synergistic effects of genetic variants of APOA5 and BTN2. A1 on dyslipidemia or metabolic syndrome. Shen GQ, Li L, Wang QK. Genetic variant R9. Q in LRP8 is associated with increased plasma triglyceride levels in patients with early- onset CAD and MI. Zhang S, Du T, Li M, Lu H, Lin X, Yu X. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Relation of high- density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular M. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 3. 56,2. Multiple Risk Factor Intervention Trial (MRFIT). Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild- to- Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, et al. Long- term follow- up of patients with acute hypertriglyceridemia- induced pancreatitis. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Chylomicronemia syndrome. US Preventive Services Task Force. Screening for lipid disorders in adults: U. S. Preventive Services Task Force recommendation statement. Rockville, Md: Agency for Healthcare Research and Quality; 2. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Vipperla K, Somerville C, Furlan A, et al. Clinical Profile and Natural Course in a Large Cohort of Patients With Hypertriglyceridemia and Pancreatitis. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV. Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Rohrich RJ, Janis JE, Pownell PH. Xanthelasma palpebrarum: a review and current management principles. Institute for Clinical Systems Improvement. Lipid management in adults. Bloomington, Minn: Institute for Clinical Systems Improvement; 2. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Secondary prevention of coronary heart disease: the role of fibric acids. University of Michigan Health System. Screening and management of lipids. Ann Arbor, Mich: University of Michigan Health System; 2. Klop B, Wouter Jukema J, Rabelink TJ, Castro Cabezas M. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, et al. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. Schaap- Fogler M, Schurr D, Schaap T, Leitersdorf E, Rund D. Long- term plasma exchange for severe refractory hypertriglyceridemia: a decade of experience demonstrates safety and efficacy. US Food and Drug Administration. Safety: statins and HIV or hepatitis C drugs: drug safety communication - interaction increases risk of muscle injury. Posted: March 1, 2. Available at http: //www. Safety/Med. Watch/Safety. Information/Safety. Alertsfor. Human. Medical. Products/ucm. Accessed: November 1, 2. US Food and Drug Administration. Safety: statin drugs - drug safety. Available at http: //www. Safety/Med. Watch/Safety. Information/Safety. Alertsfor. Human. Medical. Products/ucm. Accessed: November 1, 2. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Available at http: //www. Safety/Med. Watch/Safety. Information/Safety. Alertsfor. Human. Medical. Products/ucm. Accessed: November 1, 2. Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best- available evidence. Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, et al. Efficacy and safety of ABT- 3. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 7. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Fibrate therapy and renal function. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long- term benefit with niacin. Mc. Kenney JM, Mc. Cormick LS, Weiss S, Koren M, Kafonek S, Black DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, et al. Prescription omega- 3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega- 3 polyunsaturated fatty acids and cardiovascular diseases. Kim HS, Kim H, Jeong YJ, et al. Comparative analysis of the efficacy of omega- 3 fatty acids for hypertriglyceridaemia management in Korea. Egert S, Kannenberg F, Somoza V, Erbersdobler HF, Wahrburg U. Dietary alpha- linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 2. 00. 9; 1. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega- 3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR1. Multi- center, pl. Acebo- controlled, Randomized, double- bl. INd, 1. 2- week study with an open- label Extension .
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |